NVO/N Stock Price and Chart — BMV:NVO/N

Overview

Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

Key facts today

Novo Nordisk (NOVO_B) shares dropped 21.83% to $53.94 after lowering its sales and profit forecast for H2 2025, citing increased competition for its GLP-1 products.

Eli Lilly has raised its full-year profit and sales forecast, driven by increasing demand for its weight-loss drug Zepbound, which is aimed at capturing market share from Novo Nordisk's Wegovy.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NVO/N.